Autori: Kim SH
| Naslov | 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer (Meeting Abstract) |
| Autori | Verschraegen C Andric Zoran G Moiseenko FV Makharadze T Oleksiienko A Ruiz EP Yanez Kim SH Ahn K Park TH Ju HA Baek EH Kwon S Lee SJ Chang I Kim SH Kim HA Lee E Ohe Y |
| Info | ANNALS OF ONCOLOGY, (2024), vol. 35 br. , Suppl. 4, str. S1648-S1649 |
| Projekat | Celltrion Inc. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo) (Meeting Abstract) |
| Autori | Kao SCH Reck M Liu SV Dziadziuszko R Hochmair MJ Huemer F Gilberto de Castro J Bernabe Caro R Kim SH Kowalski DM Andric Zoran G Oancea M Kaul M Li H Danner B Lee MC Nabet BY Sugawara S |
| Info | ANNALS OF ONCOLOGY, (2024), vol. 35 br. , Suppl. 4, str. S1638-S1638 |
| Projekat | F. Hoffmann-La Roche, Ltd. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
